| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Poricoic acid AM targets pathways involved in inflammation, fibrosis, and tumor growth. As a triterpenoid from Poria cocos, it may modulate inflammatory signaling pathways such as NF-κB, MAPK, or TGF-β/Smad pathways involved in fibrosis. The compound's antitumor activity suggests effects on cancer cell proliferation and survival pathways. Its anti-fibrotic properties indicate potential activity on pathways involved in extracellular matrix deposition and tissue remodeling.
|
|---|---|
| ln Vitro |
In vitro, Poricoic acid AM exhibits antitumor activities. The compound also demonstrates potent anti-inflammatory and anti-fibrotic properties. As a triterpenoid from Poria cocos, it may inhibit the proliferation of cancer cells, reduce inflammatory cytokine production, and suppress fibrotic responses in cell-based assays. However, detailed in vitro activity data including IC₅₀ values for specific activities have not been extensively published. The compound is a triterpenoid with antitumor activities.
|
| ln Vivo |
In vivo, Poricoic acid AM has attracted research interest in chronic kidney disease (CKD) treatment due to its anti-inflammatory and anti-fibrotic properties. The compound's antitumor activities suggest potential efficacy in cancer models. As a triterpenoid from Poria cocos, a mushroom used in traditional Chinese medicine, it may contribute to the therapeutic effects of Poria cocos extracts. However, detailed in vivo study results including specific animal models, dosing regimens, and efficacy endpoints have not been extensively published.
|
| Enzyme Assay |
In vitro assays for Poricoic acid AM are not extensively documented. As a triterpenoid with antitumor, anti-inflammatory, and anti-fibrotic activities, potential assays could include cytotoxicity screening against cancer cell lines using MTT or SRB assays, evaluation of anti-inflammatory activity by measuring cytokine production in immune cells, and assessment of anti-fibrotic effects in fibroblasts or other relevant cell types by measuring collagen production or ECM-related gene expression. The compound's structure can be confirmed by NMR and MS. Purity is ≥98%.
|
| Cell Assay |
In vitro cellular assays for Poricoic acid AM could include evaluation of antitumor activity in cancer cell lines, anti-inflammatory activity in macrophages or other immune cells, and anti-fibrotic activity in fibroblasts or hepatic stellate cells. Cells are treated with the compound and cell viability, cytokine production, collagen deposition, or signaling pathway activation is measured. The compound is typically handled as a white crystal and may be soluble in organic solvents such as DMSO for cell culture applications. Storage: 2-8°C for up to 24 months.
|
| Animal Protocol |
In vivo animal experiments for Poricoic acid AM have not been extensively reported. Based on its anti-inflammatory and anti-fibrotic properties and interest in chronic kidney disease treatment, potential in vivo studies could include rodent models of CKD such as unilateral ureteral obstruction (UUO) or adenine-induced nephropathy. Antitumor activity could be evaluated in xenograft mouse models. However, detailed study protocols and results have not been published for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Poricoic acid AM have not been extensively characterized. The compound has a molecular weight of 512.72 g/mol and a molecular formula of C₃₂H₄₈O₅. As a lipophilic triterpenoid, it is expected to have reasonable membrane permeability and oral bioavailability. The compound appears as a white crystal and has low water solubility (1.8E-4 g/L at 25°C). Storage: 2-8°C for up to 24 months. Purity ≥98%.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Poricoic acid AM has not been extensively documented. As a triterpenoid from Poria cocos, a medicinal mushroom with a long history of use in traditional Chinese medicine, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that verbascolic acid (AM) has been found in calamus, and relevant data is available for reference.
Poricoic acid AM (CAS# 151200-92-9, molecular formula C₃₂H₄₈O₅, molecular weight 512.72) is a triterpenoid from Poria cocos with antitumor, anti-inflammatory, and anti-fibrotic activities. Also known as poricoic acid A 3-methyl ester. It has attracted research interest in chronic kidney disease treatment. No clinical trials or regulatory approvals have been identified. Purity ≥98%. Storage: 2-8°C for up to 24 months. |
| Molecular Formula |
C32H48O5
|
|---|---|
| Molecular Weight |
512.72
|
| Exact Mass |
512.35
|
| CAS # |
151200-92-9
|
| PubChem CID |
46882717
|
| Appearance |
White to off-white solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
627.8±55.0 °C at 760 mmHg
|
| Flash Point |
192.8±25.0 °C
|
| Vapour Pressure |
0.0±4.2 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
7.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
37
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
OC1C[C@@]2(C)C3=CCC(C(=C)C)[C@](C)(CCC(=O)OC)C3=CC[C@]2(C)C1C(C(=O)O)CCC(=C)C(C)C
|
| InChi Key |
WMPHZBWMRPCPKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H48O5/c1-19(2)21(5)10-11-22(29(35)36)28-26(33)18-32(8)25-13-12-23(20(3)4)30(6,16-15-27(34)37-9)24(25)14-17-31(28,32)7/h13-14,19,22-23,26,28,33H,3,5,10-12,15-18H2,1-2,4,6-9H3,(H,35,36)
|
| Chemical Name |
2-[2-hydroxy-6-(3-methoxy-3-oxopropyl)-3a,6,9b-trimethyl-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydrocyclopenta[a]naphthalen-3-yl]-6-methyl-5-methylideneheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9504 mL | 9.7519 mL | 19.5038 mL | |
| 5 mM | 0.3901 mL | 1.9504 mL | 3.9008 mL | |
| 10 mM | 0.1950 mL | 0.9752 mL | 1.9504 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
